Evaluation of a Day Hospital Program for Adolescents and Young Adults With Eating Disorders (UDJ-TCA)
12. juni 2026 oppdatert av: Fondation Santé des Étudiants de France
Evaluation of the Contribution of a Specialized Day Hospital for Adolescents and Young Adults With Eating Disorders: Long-Term Clinical Outcomes and Cross-Reported Experiences
This study aims to evaluate the clinical, psychological, and functional outcomes of adolescents with anorexia nervosa receiving multidisciplinary care in hospital settings. Participants are treated either in a day hospitalization program or in a full-time inpatient program, in accordance with the French national guidelines (Haute Autorité de Santé, HAS) for the management of anorexia nervosa.
The study seeks to better understand the evolution of patients' health status over time, including nutritional, psychological, and social dimensions, and to identify factors associated with treatment response. Data will be collected as part of routine clinical care without modification of the standard therapeutic management.
The results of this study may help improve clinical practices and optimize care pathways for adolescents with anorexia nervosa.
Studieoversikt
Status
Har ikke rekruttert ennå
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Antatt)
307
Fase
- Ikke aktuelt
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Barn
- Voksen
Tar imot friske frivillige
Nei
Beskrivelse
Inclusion Criteria:
- Adolescents and young adults aged 12 to 22 years
- Diagnosed with an eating disorder
- Referred for admission to the day hospital program between October 2019 and December 2023
- Provided informed consent (and parental consent for minors)
Exclusion Criteria:
- Refusal to participate
- Age below 12 years or above 22 years
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Annen: Day Hospital Program
Participants admitted to a specialized multidisciplinary day hospital program for eating disorders.
|
Participants admitted to the day hospital receive a multidisciplinary treatment program including psychiatric, medical, nutritional, and psychosocial care, delivered through structured daytime sessions without overnight stay.
|
|
Annen: Non-Admitted Participants
Participants who requested admission but were not admitted to the day hospital program.
|
Participants not admitted to the day hospital program receive usual care according to standard clinical pathways outside the specialized day hospital setting.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Change in Body Mass Index (BMI)
Tidsramme: From admission request to at least 18 months follow-up
|
From admission request to at least 18 months follow-up
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in eating disorder psychopathology assessed by EDE-Q
Tidsramme: Baseline (at admission), discharge (end of hospitalization), and follow-up at least 18 months after admission
|
Eating disorder psychopathology will be assessed using the Eating Disorder Examination Questionnaire (EDE-Q), a self-report scale ranging from 0 to 6, with higher scores indicating more severe symptoms.
The assessment will be performed at admission and discharge.
|
Baseline (at admission), discharge (end of hospitalization), and follow-up at least 18 months after admission
|
|
Change in body image concerns assessed by BSQ
Tidsramme: Baseline (at admission), discharge (end of hospitalization), and follow-up at least 18 months after admission
|
Body image concerns will be assessed using the Body Shape Questionnaire (BSQ), a self-report scale with higher scores indicating greater body dissatisfaction.
The assessment will be performed at admission and discharge.
|
Baseline (at admission), discharge (end of hospitalization), and follow-up at least 18 months after admission
|
|
Change in anxiety and depression symptoms assessed by HADS
Tidsramme: Baseline (at admission), discharge (end of hospitalization), and follow-up at least 18 months after admission
|
Anxiety and depression symptoms will be assessed using the Hospital Anxiety and Depression Scale (HADS), which includes subscales for anxiety and depression, each ranging from 0 to 21, with higher scores indicating greater symptom severity.
The assessment will be performed at admission and discharge.
|
Baseline (at admission), discharge (end of hospitalization), and follow-up at least 18 months after admission
|
|
Change in obsessive-compulsive symptoms assessed by MOCI
Tidsramme: Baseline (at admission), discharge (end of hospitalization), and follow-up at least 18 months after admission
|
Obsessive-compulsive symptoms will be assessed using the Maudsley Obsessive-Compulsive Inventory (MOCI), where higher scores indicate more severe symptoms.
The assessment will be performed at admission and discharge.
|
Baseline (at admission), discharge (end of hospitalization), and follow-up at least 18 months after admission
|
|
Change in eating disorder-related quality of life assessed by EDQoL
Tidsramme: Baseline (at admission), discharge (end of hospitalization), and follow-up at least 18 months after admission
|
Quality of life related to eating disorders will be assessed using the Eating Disorders Quality of Life (EDQoL) questionnaire, with higher scores indicating greater impairment.
The assessment will be performed at admission and discharge
|
Baseline (at admission), discharge (end of hospitalization), and follow-up at least 18 months after admission
|
|
Change in autistic traits assessed by AQ-10
Tidsramme: Baseline (at admission), discharge (end of hospitalization), and follow-up at least 18 months after admission
|
Autistic traits will be assessed using the Autism Spectrum Quotient (AQ-10), a brief screening tool with higher scores indicating more pronounced autistic traits.
The assessment will be performed at admission and discharge
|
Baseline (at admission), discharge (end of hospitalization), and follow-up at least 18 months after admission
|
|
Change in family functioning assessed by FAD-12
Tidsramme: Baseline (at admission), discharge (end of hospitalization), and follow-up at least 18 months after admission
|
Family functioning will be assessed using the Family Assessment Device (FAD-12), with higher scores indicating poorer family functioning.
The assessment will be performed at admission and discharge.
|
Baseline (at admission), discharge (end of hospitalization), and follow-up at least 18 months after admission
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Antatt)
25. mai 2026
Primær fullføring (Antatt)
24. februar 2027
Studiet fullført (Antatt)
24. februar 2027
Datoer for studieregistrering
Først innsendt
12. mai 2026
Først innsendt som oppfylte QC-kriteriene
12. juni 2026
Først lagt ut (Faktiske)
15. juni 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
15. juni 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
12. juni 2026
Sist bekreftet
1. juni 2026
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 2024-A02535-42
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .